Exagen Inc
XGN
View Detailed Chart
3.510USD
+0.150+4.46%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
79.01MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.46%
5 Days
-4.62%
1 Month
-42.36%
6 Months
-60.61%
Year to Date
-42.27%
1 Year
-33.40%
View Detailed Chart
TradingKey Stock Score of Exagen Inc
Currency: USD Updated: 2026-02-06Key Insights
Exagen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.29.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Exagen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Exagen Inc Highlights
StrengthsRisks
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.12% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 55.64M.
Fairly Valued
The company’s latest PE is -3.75, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 790.01K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.96.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
13.286
Target Price
+295.41%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Exagen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Exagen Inc Info
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Ticker SymbolXGN
CompanyExagen Inc
CEOAballi (John)
Websitehttps://exagen.com/
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
-1.78%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69226.520
-743.610 (-1.06%)
282.580
+22.390 (+8.61%)
2066.090
+14.360 (+0.70%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
